Electrical cardioversion in healthy pregnant women: safe yes, but needed?

por Crijns, H. J. G. M.
Publicado 2011

Paradigm shifts in pathophysiology and management of atrial fibrillation—a tale of the RACE trials in the Netherlands

por Crijns, H. J. G. M., Van Gelder, I. C.
Publicado 2020

Healthcare utilization and outcomes in atrial fibrillation patients treated by drug therapy versus a catheter ablation strategy

por Martinek, M, Crijns, H J G M, Essers, B, Pruckner, G J
Publicado 2023

Haemodynamic bradycardia in tachycardiomyopathy

por Mafirad, M., Blaauw, Y., van Opstal, J. M., Crijns, H. J. G. M.
Publicado 2011

Optimal long-term antithrombotic management of atrial fibrillation: life cycle management

por Pisters, R., Elvan, A., Crijns, H. J. G. M., Hemels, M. E. W.
Publicado 2018

Rate control with calcium channel blockers versus betablockers in patients with paroxysmal and persistent atrial fibrillation - data from the AFFIRM trial

por Koldenhof, T, Van Gelder, I C, Crijns, H J G M, Rienstra, M, Tieleman, R G
Publicado 2023

Statins Do Not Reduce Atrial Fibrillation After Cardiac Valvular Surgery: A Single Centre Observational Study

por Folkeringa, R. J., Tieleman, R. G., Maessen, J. G., Prins, M. H., Nieuwlaat, R., Crijns, H. J. G. M.
Publicado 2010

Stroke risk in patients with device-detected atrial high-rate episodes

por Erküner, Ö., Rienstra, M., Van Gelder, I. C., Schotten, U., Crijns, H. J. G. M., Luermans, J. G. L. M.
Publicado 2017

Gut-microbe derived TMAO and its association with more progressed forms of AF: Results from the AF-RISK study

por Nguyen, B.O., Meems, L.M.G., van Faassen, M., Crijns, H.J.G.M., van Gelder, I.C., Kuipers, F., Rienstra, M.
Publicado 2021

Mitral prolapsing volume is associated with increased cardiac dimensions in patients with mitral annular disjunction

por Luyten, P., Heuts, S., Cheriex, E., Olsthoorn, J. R., Crijns, H. J. G. M., Winkens, B., Roos-Hesselink, J. W., Sardari Nia, P., Schalla, S.
Publicado 2021

Increased plasma levels of NT-proBNP, Troponin T and GDF-15 are driven by persistent AF and associated comorbidities: Data from the AF-RISK study

por Meems, L.M.G., Artola Arita, V., Velt, M., Dudink, E.A.M.P., Crijns, H.J.G.M., Van Gelder, I.C., Rienstra, M.
Publicado 2022

Coronary artery-bronchial artery fistulas: report of two Dutch cases with a review of the literature

por Said, S. A. M., Oortman, R. M., Hofstra, J.-H., Verhorst, P. M. J., Slart, R. H. J. A., de Haan, M. W., Eerens, F., Crijns, H. J. G. M.
Publicado 2014

Determining the optimal interval for imaging surveillance of ascending aortic aneurysms

por Adriaans, B. P., Ramaekers, M. J. F. G., Heuts, S., Crijns, H. J. G. M., Bekkers, S. C. A. M., Westenberg, J. J. M., Lamb, H. J., Wildberger, J. E., Schalla, S.
Publicado 2021

Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry

por Pisters, R., van Vugt, S. P. G., Brouwer, M. A., Elvan, A., ten Holt, W. L., Zwart, P. A. G., Kirchhof, P., Crijns, H. J. G. M., Hemels, M. E. W.
Publicado 2017

Idiopathic atrial fibrillation patients rapidly outgrow their low thromboembolic risk: a 10-year follow-up study

por Weijs, B., Dudink, E. A. M. P., de Vos, C. B., Limantoro, I., Tieleman, R. G., Pisters, R., Cheriex, E. C., Luermans, J. G. L. M., Crijns, H. J. G. M.
Publicado 2019

Feasibility of TEE-guided stroke risk assessment in atrial fibrillation—background, aims, design and baseline data of the TIARA pilot study

por Dinh, T., Baur, L. H. B., Pisters, R., Kamp, O., Verheugt, F. W. A., Smeets, J. L. R. M., Cheriex, E. C., Tieleman, R. G., Prins, M. H., Crijns, H. J. G. M.
Publicado 2011

Presence and extent of cardiac computed tomography angiography defined coronary artery disease in patients presenting with syncope

por Altintas, S., Dinh, T., Marcks, N. G. H. M., Kok, M., Aerts, A. J. J., Weijs, B., Blaauw, Y., Wildberger, J. E., Das, M., Kietselaer, B. L. J. H., Crijns, H. J. G. M.
Publicado 2017

Exercise related ventricular arrhythmias are related to cardiac fibrosis in hypertrophic cardiomyopathy mutation carriers

por van Rijsingen, I. A. W., Bekkers, S. C. A. M., Schalla, S., Hermans-van Ast, J. F., Snoep, G., Alzand, B. S. N., Arens, Y. H. J. M., van den Wijngaard, A., Crijns, H. J. G. M., Pinto, Y. M.
Publicado 2011

Number of comorbidities is associated with symptom severity and arrhythmia progression in paroxysmal atrial fibrillation - Data from the RACE V study

por Van De Lande, M E, Van Deutekom, C, Geelhoed, B, Nguyen, L B O, Tieleman, R G, Weberndorfer, V, Crijns, H J G M, Hemels, M E W, De Melis, M, Schotten, U, Linz, D, Van Gelder, I C, Rienstra, M
Publicado 2023

Brady- and tachyarrhythmias in paroxysmal atrial fibrillation: results from long-term continuous electrocardiographic monitoring in RACE V

por Park Frausing, M H J, Van De Lande, M, Maass, A H, Nguyen, B O, Hemels, M E W, Tieleman, R, Koldenhof, T, De Melis, M, Linz, D, Schotten, U, Weberndorfer, V, Crijns, H J G M, Van Gelder, I C, Nielsen, J C, Rienstra, M
Publicado 2023